Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01507233 · ClinicalTrials.gov registry record · Phase 4
A Health Economic Trial in Adult Patients Undergoing Open Colectomy MA402S23B302
A Phase 4 study, sponsored by Pacira Pharmaceuticals.
- Terminated
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT01507233 is a Phase 4 study that was terminated before completion, run by Pacira Pharmaceuticals. The registered enrollment target is 5 participants.
The verdict
NCT01507233, a Phase 4 study, was terminated before completion, sponsored by Pacira Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
This study is designed to compare the standard of care against EXPAREL (bupivacaine liposome extended-release injectable suspension) to determine if total opioid consumption is reduced when using EXPAREL, therefore possibly reducing total hospitalization costs.
Interventions
- DRUG IV morphine sulfate
- DRUG EXPAREL (bupivacaine liposome injectable suspension)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2012-05 |
| Est. Completion | 2012-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01507233
The ClinicalTrials.gov registry entry for NCT01507233 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pacira Pharmaceuticals, which has 88 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which IV morphine sulfate is the first listed.
NCT01507233 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01507233 about?
NCT01507233 is a clinical study titled "A Health Economic Trial in Adult Patients Undergoing Open Colectomy MA402S23B302". This study is designed to compare the standard of care against EXPAREL (bupivacaine liposome extended-release injectable suspension) to determine if total opioid consumption is reduced when using EXPAREL, therefore possibly reducing total hospitalization costs.
What is the current status of trial NCT01507233?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2012-05. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01507233?
The interventions under investigation include: IV morphine sulfate (DRUG), EXPAREL (bupivacaine liposome injectable suspension) (DRUG).
Who is sponsoring clinical trial NCT01507233?
This trial is sponsored by Pacira Pharmaceuticals, which has 88 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.